The Strat-AF study enrolled 194 patients (mean age 78.1 years) with atrial fibrillation to evaluate biological markers for predicting cerebral bleeding risk, with follow-up ongoing.
Observational (n=194)
No
Do biological markers (circulating and imaging-based) improve the prediction of bleeding risk in older patients with atrial fibrillation on oral anticoagulants?
The Strat-AF study is an ongoing prospective cohort study designed to evaluate whether circulating and imaging-based biomarkers can improve bleeding risk stratification in older patients with atrial fibrillation on oral anticoagulants.
Background and Objectives: In anticoagulated atrial fibrillation (AF) patients, the validity of models recommended for the stratification of the risk ratio between benefits and hemorrhage risk is limited. Cerebral small vessel disease (SVD) represents the pathologic substrate for primary intracerebral hemorrhage and ischemic stroke. We hypothesize that biological markers—both circulating and imaging-based—and their possible interaction, might improve the prediction of bleeding risk in AF patients under treatment with any type of oral anticoagulant. Materials and Methods: The Strat-AF study is an observational, prospective, single-center hospital-based study enrolling patients with AF, aged 65 years or older, and with no contraindications to magnetic resonance imaging (MRI), referring to Center of Thrombosis outpatient clinic of our University Hospital for the management of oral anticoagulation therapy. Recruited patients are evaluated by means of a comprehensive protocol, with clinical, cerebral MRI, and circulating biomarkers assessment at baseline and after 18 months. The main outcome is SVD progression—particularly microbleeds—as a selective surrogate marker of hemorrhagic complication. Stroke occurrence (ischemic or hemorrhagic) and the progression of functional, cognitive, and motor status will be evaluated as secondary outcomes. Circulating biomarkers may further improve predictive potentials. Results: Starting from September 2017, 194 patients (mean age 78.1 ± 6.7, range 65–97; 61% males) were enrolled. The type of AF was paroxysmal in 93 patients (48%), and persistent or permanent in the remaining patients. Concerning the type of oral anticoagulant, 57 patients (29%) were on vitamin K antagonists, and 137 (71%) were on direct oral anticoagulants. Follow-up clinical evaluation and brain MRI are ongoing. Conclusions: The Strat-AF study may be an essential step towards the exploration of the role of a combined clinical biomarker or multiple biomarker models in predicting stroke risk in AF, and might sustain the incorporation of such new markers in the existing stroke prediction schemes by the demonstration of a greater incremental value in predicting stroke risk and improvement in clinical outcomes in a cost-effective fashion.
Poggesi et al. (2019) conducted an observational in Atrial fibrillation (n=194). Biological markers (circulating and imaging-based) was evaluated on Small vessel disease (SVD) progression, particularly microbleeds. The Strat-AF study enrolled 194 patients (mean age 78.1 years) with atrial fibrillation to evaluate biological markers for predicting cerebral bleeding risk, with follow-up ongoing.